Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact ofAPPDose and Preclinical Studies of a γ‐Secretase Modulator

Abstract

ObjectiveThe retromer complex plays an essential role in intracellular endosomal sorting. Deficits in the retromer complex are linked to enhanced Aβ production. The levels of the components of the retromer complex are reported to be downregulated in Alzheimer disease (AD). Down syndrome (DS) shares neuropathological features with AD. Recent evidence points to dysregulation of the retromer complex in DS. The mechanisms underlying retromer deficits in DS and AD are poorly understood.MethodsWe measured the levels of retromer components in the frontal cortex of cases of DS‐AD (AD in DS) as well as DS; the frontal cortex of a person partially trisomic (PT‐DS) for human chromosome 21 (HSA21), whose genome had only the normal 2 copies of theAPPgene, was also examined. We also analyzed these proteins in the Dp16 mouse model of DS. To further explore the molecular mechanism for changes in the retromer complex, we treated Dp16 mice with a γ‐secretase modulator (GSM; 776890), a treatment that reduces the levels of Aβ42 and Aβ40.ResultsWe found VPS26A, VPS26B, and VPS29, but not VPS35, were significantly reduced in both DS and DS‐AD, but not in PT‐DS. Downregulation of VPS26A, VPS26B, and VPS29 was recapitulated in the brains of old Dp16 mice (at 16 months of age) and required increasedAppgene dose. Significantly, GSM treatment completely prevented reductions of the retromer complex.InterpretationOur studies point to increasedAPPgene dose as a compromising retromer function in DS and suggest a causal role for Aβ42 and Aβ40. ANN NEUROL 2023;94:245–258